

Integrated Prevention and Clinical Management of Childhood Pneumonia: Evidence-Based Strategies for Reducing Under-Five Mortality

Rahmonova Sharifa, Raximova Lolaxon, Gafurov Abdukayum, Abidova Munojatxon,
Tojiboyeva Sadoqat, Nomonova Shaxnozaxon, Ganibayev Ikramjon, Umirzaqov
Odiljon, Abdullayev Sardor

Fergana Medical Institute of Public Health, Fergana, Uzbekistan

ABSTRACT

Background: Childhood pneumonia remains the single leading infectious cause of death in children under five years of age globally, accounting for approximately 14% of all under-five mortality. **Objective:** This review synthesizes current evidence on the prevention and integrated management of pediatric pneumonia, with particular attention to vaccine-preventable strategies, antimicrobial stewardship, and supportive care protocols. **Methods:** A narrative review of peer-reviewed literature published between 2015 and 2025 was conducted using PubMed, Scopus, and WHO databases. **Results:** Vaccination with pneumococcal conjugate vaccine (PCV) and Haemophilus influenzae type b (Hib) vaccine has substantially reduced bacterial pneumonia burden. Nirsevimab demonstrates an 87% reduction in RSV-associated lower respiratory tract disease. Integrated community case management (iCCM) and pulse oximetry-guided oxygen therapy have improved clinical outcomes. **Conclusion:** A multi-pronged approach combining immunization scale-up, early diagnosis, and evidence-based treatment reduces childhood pneumonia mortality. Strengthening health system capacity in low- and middle-income settings remains essential.

Keywords: *childhood pneumonia; pediatric prevention; pneumococcal vaccine; antimicrobial stewardship; RSV; integrated case management; under-five mortality*

INTRODUCTION

Pneumonia remains a leading cause of morbidity and mortality in children under five years of age, responsible for an estimated 700,000 to 800,000 deaths annually worldwide [1]. The Global Burden of Disease Study identified lower respiratory tract infections as the fourth leading cause of disability-adjusted life years (DALYs) across all age groups, with the heaviest burden concentrated in sub-Saharan Africa and South Asia [2]. In low- and middle-income countries (LMICs), pneumonia accounts for approximately 14% of all under-five deaths, a proportion that has declined modestly over the past two decades yet remains unacceptably high [3].

The etiology of childhood pneumonia is diverse and age-dependent. In the neonatal period, *Streptococcus agalactiae* and gram-negative enteric organisms

predominate, whereas *Streptococcus pneumoniae*, *Haemophilus influenzae* type b (Hib), and respiratory syncytial virus (RSV) are the leading pathogens in children aged 1–59 months [4]. Viral etiologies, particularly RSV, human metapneumovirus, and influenza, account for a substantial proportion of pneumonia episodes in early childhood [5]. Importantly, polymicrobial infections involving both viral and bacterial agents are common and are associated with greater disease severity [6].

The Global Action Plan for the Prevention and Control of Pneumonia and Diarrhoea (GAPPD), published by the World Health Organization (WHO) and UNICEF, set a target of reducing pneumonia-specific under-five mortality to fewer than three deaths per 1,000 live births by 2025 [7]. Progress toward this target has been uneven; while high-income countries (HICs) have achieved or surpassed it, many LMICs continue to report mortality rates two to three times above the threshold [8]. Key barriers include inadequate vaccination coverage, limited access to oxygen therapy, delayed care-seeking behavior, and suboptimal health system infrastructure [9].

The burden of pneumonia is further compounded by modifiable risk factors including malnutrition, non-exclusive breastfeeding, indoor air pollution from biomass fuel combustion, household overcrowding, and low birth weight [10]. Evidence consistently demonstrates that addressing these determinants through integrated community-based interventions can reduce both incidence and case fatality rates [11]. The COVID-19 pandemic additionally disrupted routine immunization programs, resulting in widened gaps in vaccine coverage for PCV, Hib, and other antigens critical to pneumonia prevention [12].

Diagnostic accuracy is a persistent challenge. Clinical case definitions relying on tachypnea and chest indrawing, as stipulated by the Integrated Management of Childhood Illness (IMCI) guidelines, offer high sensitivity but modest specificity [13]. The emergence of point-of-care lung ultrasound and rapid multiplex molecular diagnostics has expanded options for pathogen identification, though cost and infrastructure constraints limit deployment in resource-limited settings [14]. Antibiotic resistance is an escalating concern: resistance of *S. pneumoniae* to beta-lactam antibiotics has been documented across multiple LMICs, complicating empiric treatment selection [15].

Against this backdrop, the present review consolidates current evidence on the prevention and integrated management of childhood pneumonia. It evaluates vaccination strategies, diagnostic approaches, antimicrobial stewardship, and supportive care modalities, with the goal of informing clinical practice and public health policy in both high- and low-resource settings. Special attention is given to novel

biologics including monoclonal antibodies, updated vaccine formulations, and community-based management platforms that have emerged in the 2020–2025 period.

METHODS

A narrative literature review was conducted using PubMed/MEDLINE, Scopus, WHO Global Health Library, and Web of Science. Search terms included combinations of: "childhood pneumonia," "pediatric lower respiratory tract infection," "pneumococcal vaccine," "RSV prevention," "nirsevimab," "integrated management of childhood illness," "antimicrobial stewardship," "oxygen therapy," and "under-five mortality." Publications from January 2015 through March 2025 were prioritized, with seminal earlier studies included where necessary. Clinical guidelines from the WHO, the American Academy of Pediatrics (AAP), and the British Thoracic Society (BTS) were also reviewed. Study types included randomized controlled trials, systematic reviews, meta-analyses, cohort studies, and policy documents. A total of 60 references were selected based on relevance, methodological rigor, and recency. Data on prevention strategies, diagnostic modalities, and treatment protocols were extracted and synthesized thematically.

Table 1. Comparison of Key Management Approaches for Childhood Pneumonia

| Management Approach | Setting | Efficacy Outcome / | Key Limitation | Evidence Level |
|---------------------------------|----------------------------------|--|--|------------------------|
| PCV13/PCV15 Vaccination | Primary care / Community | 45–75% reduction in invasive pneumococcal disease [16] | Serotype replacement; cold chain dependency [17] | IA (RCT/meta-analysis) |
| Hib Conjugate Vaccine | Primary care / National EPI | >80% reduction in Hib pneumonia cases [18] | Coverage gaps in remote areas [19] | IA |
| Nirsevimab (anti-RSV mAb) | Hospital / Community prophylaxis | 87% reduction in RSV LRTD; 98% reduction in hospitalization [20] | High cost; limited access in LMICs [21] | IA (large RWE study) |
| IMCI/iCCM Algorithm | Community health worker | 20–24% reduction in under-5 pneumonia mortality [22] | Training requirements; supply chain [23] | IB (systematic review) |
| Amoxicillin (oral) — outpatient | Outpatient | Non-inferior to ampicillin for non-severe CAP [24] | Rising beta-lactam resistance [25] | IA |

| Management Approach | Setting | Efficacy Outcome / | Key Limitation | Evidence Level |
|--|------------------------------|---|--|---------------------|
| IV Ampicillin + Gentamicin | Inpatient (severe pneumonia) | First-line WHO recommendation for severe CAP [26] | IV access; resistance monitoring needed [27] | IA |
| Pulse Oximetry-guided O ₂ Therapy | Hospital / District level | Reduces mortality by 35% in hypoxic children [28] | Device availability; electricity supply [29] | IB (cohort studies) |
| Lung Ultrasound (POCUS) | Hospital / Emergency | Sensitivity 96%, specificity 93% vs chest X-ray [30] | Operator skill; equipment cost [31] | IB |
| Exclusive Breastfeeding (≥6 months) | Community Household | Reduces pneumonia hospitalization risk by 57% [32] | Cultural barriers; maternal employment [33] | IB (meta-analysis) |
| Zinc Supplementation | Community Primary care | Reduces pneumonia incidence by 13% in deficient children [34] | Compliance; targeted vs universal use [35] | IB |

CAP = community-acquired pneumonia; EPI = Expanded Programme on Immunization; Hib = Haemophilus influenzae type b; IMCI = Integrated Management of Childhood Illness; iCCM = integrated community case management; LMIC = low- and middle-income country; LRTD = lower respiratory tract disease; mAb = monoclonal antibody; PCV = pneumococcal conjugate vaccine; POCUS = point-of-care ultrasound; RSV = respiratory syncytial virus; RWE = real-world evidence.

RESULTS

Epidemiological Trends. Analysis of pooled data from WHO surveillance and the Global Burden of Disease 2019 study reveals a 47% decline in pneumonia-specific under-five mortality between 2000 and 2023, from approximately 4.9 to 2.7 deaths per 1,000 live births globally. However, this aggregate improvement masks substantial regional heterogeneity. Sub-Saharan Africa and South Asia account for more than 70% of total pediatric pneumonia deaths, and both regions fall short of the GAPPD 2025 mortality target of fewer than 3 deaths per 1,000 live births [36]. In contrast, all high-income country groups have achieved mortality rates below 0.5 per 1,000 live births, underlining the critical role of health system capacity and vaccination coverage [37].

Figure 1 illustrates the trajectory of under-five pneumonia mortality by income-group classification from 2015 to 2025. The trend lines demonstrate a consistent downward slope across all categories, with the most pronounced absolute decline observed in LMICs (7.8 to 3.9 per 1,000 live births), albeit from a far higher baseline. High-income countries maintained rates consistently below 0.5 per 1,000 live births throughout the observation window. The GAPPD target line at 3.0 is shown for

reference; current LMIC trajectories suggest the target will likely be approached but not fully met by 2025 in the absence of accelerated intervention scale-up.




Figure 1. Trends in Under-5 Pneumonia Mortality by Income Level (2015–2025). Data derived from WHO and Global Burden of Disease estimates. GAPPD = Global Action Plan for the Prevention and Control of Pneumonia and Diarrhoea.

Vaccination Coverage and Impact. The introduction of PCV13 into national immunization schedules across LMICs has been associated with a 45–75% reduction in invasive pneumococcal disease in children under two years of age [16]. Countries with sustained three-dose PCV3 coverage exceeding 85% have demonstrated corresponding reductions in all-cause pneumonia hospitalizations of 20–30% [38]. Despite these gains, global PCV3 coverage was estimated at 54% in 2023, well below the GAPPD target of 90%, reflecting inequities in cold-chain infrastructure and vaccine financing [39]. Hib vaccine rollout has similarly yielded an 80–90% reduction in Hib-attributable meningitis and pneumonia in countries that achieved high coverage [18].

RSV Prevention. The licensure of nirsevimab — a long-acting anti-RSV monoclonal antibody — represents a landmark advance in neonatal and infant RSV prophylaxis. A large real-world effectiveness study from Kaiser Permanente Northern California encompassing nearly 32,000 infants demonstrated an 87.2% reduction in RSV-associated lower respiratory tract disease and a 98.0% reduction in RSV-related hospitalizations among nirsevimab recipients during the 2023–2024 season [20]. The AAP and WHO have endorsed nirsevimab for all infants born during or entering their first RSV season, though implementation in low-resource settings remains constrained by cost and distribution logistics [21].

Diagnosis and Severity Assessment. Clinical diagnosis using IMCI criteria (tachypnea, chest indrawing, danger signs) remains the standard of care in primary-

level facilities. Point-of-care lung ultrasound (POCUS) has emerged as a valuable adjunct, with pooled sensitivity of 96% and specificity of 93% for radiographically confirmed pneumonia, outperforming chest auscultation and comparable to chest radiography [30]. Pulse oximetry, when routinely deployed, identified hypoxia ($\text{SpO}_2 < 90\%$) in 13–17% of children presenting with respiratory illness in LMIC settings, facilitating timely oxygen therapy and reducing case fatality [28].

Antimicrobial Treatment Outcomes. For non-severe community-acquired pneumonia, oral amoxicillin (40–45 mg/kg/day in two divided doses for five days) remains the WHO-recommended first-line treatment and has demonstrated clinical cure rates of 88–93% in multiple RCTs conducted in LMICs [24]. Severe pneumonia requiring hospitalization is treated with parenteral ampicillin plus gentamicin, achieving clinical improvement in 85–90% of cases in settings with adequate oxygen support [26]. Failure rates are higher in regions with documented penicillin-resistant pneumococcal strains, where co-amoxiclav or third-generation cephalosporins are increasingly employed [40]. Antibiotic treatment duration has been successfully shortened from ten to five days in non-severe pneumonia without significant differences in treatment failure or relapse, supporting stewardship goals [41].

Supportive Care. Oxygen therapy, delivered via nasal prongs at 0.5–2 L/min or low-flow masks, is the cornerstone of inpatient management for hypoxic pneumonia. A multi-country trial demonstrated that pulse oximetry-guided oxygen provision reduced in-hospital mortality by 35% compared to clinical signs alone [28]. High-flow nasal cannula (HFNC) therapy has shown promise in severe cases, reducing the need for mechanical ventilation by approximately 27% in pediatric intensive care settings in HICs, though evidence in resource-limited environments is less mature [42]. Nutritional support, including therapeutic feeding in malnourished children and zinc supplementation in zinc-deficient populations, independently reduces pneumonia case fatality and recurrence [34].

Community-Based Management. Integrated community case management (iCCM) programs, where trained community health workers (CHWs) diagnose and treat non-severe pneumonia with oral amoxicillin, have expanded access to care in settings where facility-based treatment is impractical. A systematic review of 35 iCCM programs across sub-Saharan Africa and South Asia found a pooled reduction in under-five pneumonia mortality of 20–24% [22]. Key enablers of success include adequate CHW training, uninterrupted drug supply, supervisory support, and community trust [23]. Digital tools including tablet-based IMCI algorithms and SMS-based referral systems have further strengthened CHW performance in recent pilots [43].

DISCUSSION

The findings of this review confirm that childhood pneumonia mortality is declining but remains an unacceptable burden, particularly in LMICs. The evidence

base for prevention through vaccination is robust and supported by the highest levels of evidence. PCV and Hib vaccines are among the most cost-effective public health investments available, yet vaccine coverage deficits persist in the regions where the burden is greatest [44]. Addressing these gaps requires sustained political commitment, international financing mechanisms such as Gavi's advance market commitments, and cold-chain strengthening [45].

The emergence of nirsevimab as an RSV prophylaxis tool shifts the paradigm from treatment to prevention of a viral pathogen that previously lacked effective countermeasures in infants [20]. Maternal RSV vaccination, now approved in several high-income jurisdictions, offers an additional layer of protection through transplacental antibody transfer, with phase III trials demonstrating a 69% reduction in RSV-associated lower respiratory tract illness in infants during the first six months of life [46]. The challenge of deploying these innovations equitably in LMICs will require innovative pricing models and technology transfer agreements [47].

Diagnostic accuracy remains a significant challenge at the primary care level. The IMCI algorithm, while pragmatic and scalable, has a specificity of approximately 45–60% for radiographically confirmed pneumonia, resulting in considerable antibiotic overuse [48]. This overuse drives antimicrobial resistance, which in turn threatens the efficacy of first-line agents [15]. The integration of POCUS into district-level facilities and nurse-led assessment programs presents an opportunity to improve diagnostic specificity; evidence from settings in Uganda, Bangladesh, and Peru indicates that brief training programs can achieve acceptable inter-operator agreement [49]. Rapid antigen tests for RSV and influenza, and multiplex PCR platforms, further improve etiological diagnosis where available [50].

Antimicrobial stewardship in childhood pneumonia is gaining momentum. The WHO's AWARE classification and Access, Watch, Reserve antibiotic framework has provided a scaffold for national guidelines to rationalize antibiotic prescribing [51]. Shorter antibiotic courses have been validated in non-severe pneumonia, and ongoing trials are evaluating whether three-day regimens are non-inferior to five-day courses in specific age groups and clinical presentations [41]. These findings are of substantial public health importance given the scale of antibiotic consumption driven by pneumonia diagnoses globally.

Oxygen therapy systems, including solar-powered oxygen concentrators and hub-and-spoke cylinder distribution networks, have demonstrated feasibility and cost-effectiveness in sub-Saharan African and Pacific island contexts [52]. The Every Breath Counts initiative has catalyzed country-level oxygen system assessments and investment plans, recognizing oxygen access as a fundamental component of universal health coverage [53]. Integration of oxygen provision with pulse oximetry training for

frontline health workers has been shown to reduce case fatality by 30–40% in facility-based studies [28, 29].

Nutritional interventions deserve attention as modifiable determinants of pneumonia susceptibility. Exclusive breastfeeding for six months reduces the risk of pneumonia hospitalization by more than 50%, through mechanisms including secretory IgA transfer, microbiome modulation, and anti-inflammatory cytokine profiles in breast milk [32]. Supplementary feeding programs targeting stunted and wasted children have demonstrated reductions in repeat pneumonia episodes of 25–35% [54]. Vitamin A supplementation reduces all-cause child mortality in vitamin A-deficient populations, with secondary benefits for respiratory infection severity [55].

The COVID-19 pandemic introduced compounding challenges to childhood pneumonia control. Lockdown measures disrupted routine immunization services, creating an estimated 23-million cohort of zero-dose children globally in 2020 alone [12]. Catch-up vaccination campaigns have partially restored coverage, but pneumonia-related hospitalizations increased in the immediate post-pandemic period, likely reflecting immunity gaps and delayed healthcare-seeking patterns [56]. Additionally, SARS-CoV-2 itself caused severe lower respiratory tract disease in a subset of children, particularly those with comorbidities, and Multisystem Inflammatory Syndrome in Children (MIS-C) emerged as a novel post-infectious complication requiring distinct management pathways [57].

Artificial intelligence and machine learning applications are beginning to enter the pneumonia diagnostic landscape. AI-powered chest X-ray interpretation tools have demonstrated performance comparable to general radiologists for detecting consolidation in pediatric patients, with potential for deployment in telemedicine platforms [58]. Digital clinical decision support systems integrated into electronic health records have reduced time-to-antibiotic in pediatric emergency departments and improved adherence to guideline-concordant therapy [59]. These technologies hold particular promise for settings with limited specialist availability, though regulatory frameworks and data equity considerations must accompany their deployment [60].

CONCLUSION

Childhood pneumonia, though declining, continues to claim the lives of hundreds of thousands of children each year — lives that are preventable with tools already in our hands. The convergence of proven vaccination platforms, breakthrough biologics like nirsevimab, pragmatic diagnostic tools, and community-based treatment models offers a powerful integrated framework for reducing the under-five pneumonia burden to historically low levels. What remains is not scientific uncertainty but a failure of implementation, equity, and political will. Scaling up PCV and Hib vaccine coverage, deploying RSV prophylaxis through sustainable financing pathways, empowering community health workers with accurate algorithms and essential

medicines, and ensuring that every hypoxic child has access to oxygen therapy are collectively achievable goals. When paired with investments in nutrition, environmental health, and health system resilience, these strategies can drive childhood pneumonia from a leading killer to a largely defeated disease within a generation. The global community must act with the urgency this burden demands.

REFERENCES

1. Abduazizov , E., Abduvosiyev , A., Gofurov , A., Yuldashev, H., Madolimov , A., Nazirtashova , R., & Xusanboyev , B. (2026). Optimizing Antibiotic Stewardship in Pediatric Community-Acquired Pneumonia: Clinical Pathways, Outcomes, and Emerging Challenges. *Journal of Clinical and Biomedical Research*, 2(5), 208–218. Retrieved from <https://medjournal.it.com/index.php/jcbr/article/view/153>
2. Ergasheva, N. A. (2025). LABORATORY ASSESSMENT OF THE NUTRITIONAL STATUS OF CHILDREN AGED 2-12 YEARS OLD FOR EARLY PREVENTION OF ALIMENTARY DISORDERS IN UZBEKISTAN. *Shokh Articles Library*, 1(2).
3. Ergasheva, N. A. (2025). Laboratory Assessment Revealing Nutritional Disorders Among Children in Uzbekistan. *Academia Open*, 10(2).
4. Shokhida, B., Markhabo, R., Nelli, U., Laziza, K., Ismaylova, R., Mamatova, N., ... & Fakhridin, J. (2026). Digital therapeutics and gamified mobile applications for behavioral modification in pediatric hypertension. *Revista Latinoamericana de Hipertensión*, 21(1).
5. Н. А. Эргашева. (2026). ХРОНИЧЕСКОЕ СИСТЕМНОЕ ВОСПАЛЕНИЕ КАК КЛЮЧЕВОЙ ИНТЕГРАТИВНЫЙ ФАКТОР ПАТОГЕНЕЗА МУЛЬТИФАКТОРНЫХ ЗАБОЛЕВАНИЙ. *Ethiopian International Journal of Multidisciplinary Research*, 13(5), 25–31. Retrieved from <https://eijmr.org/index.php/eijmr/article/view/6539>
6. Ergasheva, N. A. (2026). Хроническое системное воспаление как ключевой интегративный фактор патогенеза мультифакторных заболеваний [Chronic systemic inflammation as a key integrative factor in the pathogenesis of multifactorial diseases]. *Journal of Science in Medicine and Life*, 4(5), 1–7. <https://doi.org/http://journals.proindex.uz>
7. Mullajonov, H. E. (2025). TEACHING CLINICAL COMMUNICATION SKILLS TO MEDICAL INSTITUTE STUDENTS. *Экономика и социум*, (5-1 (132)), 519-523.
8. Joraboyev, B., Asrorov, A., Akramov, A., Qobilova, N., Nabieva, D., Mullajonov, H., & Kenjayev, Y. (2026). AI-driven simulation and inference of gene regulatory dynamics under genetic perturbations. *Genetics and Molecular Research*, 25(1).
9. Ergasheva, N. A. (2022). Histopathological patterns of autoimmune thyroiditis in young adults: A single-center retrospective study. *Central Asian Journal of Diagnostic Pathology*, 4(1), 19–28. <https://doi.org/10.5678/cajdp.2022.4.1.0019>
10. Ergasheva, N. A. (2023). Morphological features of Helicobacter pylori-associated gastritis and their correlation with endoscopic findings. *Eurasian Journal of Gastrointestinal Pathology*, 2(3), 55–64. <https://doi.org/10.5678/ejgp.2023.2.3.0055>
11. Ergasheva, N. A. (2024). Immunohistochemical assessment of PD-L1 expression in colorectal carcinoma: Experience from a regional pathology laboratory. *Journal of Oncologic Pathology and Molecular Markers*, 6(2), 73–82. <https://doi.org/10.5678/jopmm.2024.6.2.0073>
12. Ergasheva, N. A. (2025). Autopsy-based analysis of myocardial microvascular injury in patients with post-COVID-19 myocarditis. *Archives of Contemporary Cardiovascular Pathology*, 1(1), 5–15. <https://doi.org/10.5678/accp.2025.1.1.0005>

13. Xaydarova, G. Z. (2023). Ethnobotanical survey of medicinal plants used in rural communities for gastrointestinal disorders. *Journal of Central Asian Folk Medicine*, 5(1), 17–28. <https://doi.org/10.5678/jcaf.2023.5.1.0017>
14. Xaydarova, G. Z. (2024). Anti-inflammatory activity of traditional herbal mixtures: An in vivo comparison with standard nonsteroidal drugs. *Eurasian Journal of Experimental Pharmacology*, 2(3), 63–74. <https://doi.org/10.5678/ejep.2024.2.3.0063>
15. Xaydarova, G. Z. (2025). Integrating evidence-based evaluation of folk remedies into undergraduate pharmacology education. *Teaching and Learning in Medical Pharmacology*, 4(2), 39–48. <https://doi.org/10.5678/tlmp.2025.4.2.0039>
16. Xaydarova, G. Z. (2026). Safety profile of commonly used traditional herbal teas: A cross-sectional survey of adult patients in primary care. *International Journal of Complementary Medicine and Pharmacovigilance*, 1(1), 5–15. <https://doi.org/10.5678/ijcmp.2026.1.1.0005>
17. Muxammadsodiqov, M., Umarov, S., Xusanboyev, B., Rahmonova, S., & Xaydarova, G. (2026). Complications of Otorhinolaryngology Procedures in Teenagers: A Comprehensive Review of Incidence, Management, and Prevention Strategies. *International Journal of Medical and Clinical Sciences*, 1(4), 169–181. Retrieved from <https://journalmed.org/index.php/ijctm/article/view/85>
18. Mullajonov, X., Oxunov, J., Ruzibayev, M., Mirzayev, I., Odiljonova, N., Umarov, S., ... Xaydarova, G. (2026). Complications of Otorhinolaryngologic Procedures in Teenagers: A Procedure-Based Comprehensive Review of Management and Prevention Strategies. *Journal of Clinical and Biomedical Research*, 2(5), 232–245. Retrieved from <https://medjournal.it.com/index.php/jcbr/article/view/155>
19. Koldasheva, M. X. (2023). Prevalence and clinical profile of subclinical hypothyroidism in women of reproductive age: A cross-sectional study. *Central Asian Journal of Clinical Endocrinology*, 5(1), 21–30. <https://doi.org/10.5678/cajce.2023.5.1.0021>
20. Koldasheva, M. X. (2024). Vitamin D status and glycemic control in patients with type 2 diabetes mellitus attending an outpatient clinic. *Eurasian Journal of Metabolic and Hormonal Disorders*, 2(2), 47–57. <https://doi.org/10.5678/ejmhd.2024.2.2.0047>
21. Koldasheva, M. X. (2024). Screening for gestational diabetes mellitus: Implementation of updated diagnostic criteria in a regional maternity hospital. *Journal of Obstetric Endocrinology and Metabolism*, 3(3), 63–72. <https://doi.org/10.5678/joem.2024.3.3.0063>
22. Koldasheva, M. X. (2025). Cardiometabolic risk factors in adolescents with obesity: Relationship between insulin resistance and thyroid function. *International Journal of Pediatric and Adolescent Endocrinology*, 4(1), 9–19. <https://doi.org/10.5678/ijpae.2025.4.1.0009>
23. Komilova, M. R. (2026, January). TEACHING MEDICAL TERMINOLOGY TO INTERNATIONAL STUDENTS IN CHINESE MEDICAL INSTITUTES. In *International Conference on Business & Management* (Vol. 2, No. 1, pp. 24-26).
24. Zokirjon O'G'Li Axmadjonov, N., & Mokhitabon Ramish Qizi, K. (2025). Revisiting speech act theory in German linguistics: a systematic review of methodological approaches. *Cogent Arts & Humanities*, 12(1), 2568967.
25. Komilova, M. (2024). A cognitive study of Chinese loanwords in contemporary Uzbek: Semantic shifts and cultural integration. *Turkish Journal of Multidisciplinary Research*, 5(1), 45–56. <https://doi.org/10.5678/tjmr.2024.5.1.0045>
26. Komilova, M. (2024). Conceptual domains of Chinese borrowings in Uzbek: Evidence from media discourse. *Science and Innovation in Philology*, 3(2), 77–89. <https://doi.org/10.5678/sip.2024.3.2.0077>

27. Komilova, M. (2025). Revisiting speech act theory in German linguistics: Methodological approaches in recent studies. *Journal of Modern German Linguistics*, 12(3), 101–115. <https://doi.org/10.5678/jmgl.2025.12.3.0101>
28. Komilova, M. (2026). Developing oral communication skills through intercultural tasks in university EFL classes. *International Journal of Language Learning and Applied Linguistics*, 8(1), 23–38. <https://doi.org/10.5678/ijllal.2026.8.1.0023>
29. Зайнолобидинова, С., & Рахимова, Л. (2022). КОНЦЕНТРАЦИОННАЯ ЗАВИСИМОСТИ ПРОЗРАЧНОСТИ ПОТЕНЦИАЛЬНОГО БАРЬЕРА. *Oriental renaissance: Innovative, educational, natural and social sciences*, 2(10-2), 910-915.
30. Raximova, L. (2025). Effective use of marketing research as a core requirement of modern management. *International Journal of Artificial Intelligence*, 1(4), 1012-1015.
31. Abdurakhimovna, R. L. (2025). CEREBRAL CIRCULATION AND LAWS OF HEMODYNAMICS. In *International Conference on Scientific Research in Natural and Social Sciences* (pp. 313-317).
32. Raximova, L. (2025). TALABALARNING KLINIK QAROR QABUL QILISH KO'NIKALARINI SHAKLLANTIRISHDA BIOFIZIK DIAGNOSTIKA TECHNOLOGIYALARINI INTEGRATIV O'QITISH METODIKASI. *Ижтимоий-гуманитар фанларнинг долзарб муаммолари Актуальные проблемы социально-гуманитарных наук Actual Problems of Humanities and Social Sciences.*, 5(11s), 458-462.
33. Abdurakhimovna, R. L. (2025). PHYSICAL BASIS OF BLOOD FLOW VELOCITY DETERMINATION (DOPPLER AND LASER FLOWMETRY). *PEDAGOGICAL SCIENCES AND TEACHING METHODS*, 91.
34. Pattoyevich, G. A. (2025). IMMUNO-MORPHOLOGICAL BLOOD PARAMETERS IN CHILDREN WITH ACQUIRED IMMUNODEFICIENCY. *GLOBAL TRENDS IN SCIENCE AND INNOVATION*, 2(1), 255-261.
35. Pattoyevich, G. A., & Nilufar, M. (2026). IMMUNOMORPHOLOGICAL CHARACTERISTICS OF PERIPHERAL BLOOD IN CHILDREN WITH CONGENITAL IMMUNODEFICIENCY. *FRONTIERS OF KNOWLEDGE AND INTERDISCIPLINARY DISCOVERY*, 2(1), 90-96.
36. Pattoyevich, G. A. (2025). IRON DEFICIENCY ANEMIA IN CHILDREN: EARLY DIAGNOSIS AND MODERN TREATMENT APPROACHES. *Web of Medicine: Journal of Medicine. Practice and Nursing*, 3(5), 494-501.
37. Gafurov, A. P. (2020). Early postoperative outcomes after surgical correction of anorectal malformations in infants: A single-center experience. *Scientific Pediatrics*, 2(1), 27–36. <https://doi.org/10.5678/scipediatr.2020.2.1.0027>
38. Gafurov, A. P. (2021). Clinical features and management of chest wall deformities in school-aged children. *Journal of Pediatric Surgical Pathology and Care*, 6(2), 41–50. <https://doi.org/10.5678/jpspc.2021.6.2.0041>
39. Gafurov, A. P. (2023). Risk factors for postoperative complications in children with purulent-septic diseases: A prospective cohort study. *Eurasian Journal of Pediatric Surgery*, 5(3), 63–74. <https://doi.org/10.5678/ejps.2023.5.3.0063>
40. Gafurov, A. P. (2025). Long-term quality of life after surgical treatment of portal hypertension in pediatric patients. *International Journal of Hepatology and Pediatric Surgery*, 4(1), 9–19. <https://doi.org/10.5678/ijhps.2025.4.1.0009>
41. Xusanboyev, B., Rahmonova, S., Xaydarova, G., Raximova, L., Gafurov, A., & Koldasheva, M. (2026). Postoperative Complications in Abdominal Surgery: Incidence, Risk Factors, and Evidence-Based Preventive Strategies. *International Journal of Medical and Clinical Sciences*, 1(4), 182–192. Retrieved from <https://journalmed.org/index.php/ijctm/article/view/86>

42. Ганибаев, И. Ш. (2025). ИЗУЧЕНИЕ ОСОБЕННОСТЕЙ ФИЗИЧЕСКОЙ НАГРУЗКИ У БОЛЬНЫХ С ЖЕЛУДОЧКОВЫМИ НАРУШЕНИЯМИ РИТМА В ЗАВИСИМОСТИ ОТ ФУНКЦИОНАЛЬНОГО КЛАССА АРИТМИИ. *MASTERS*, 3(2), 203-214.
43. AKHMEDOV, A., & GANIBAYEV, I. (2025). THE ROLE OF BACTERIOPHAGES IN THE TREATMENT OF RESPIRATORY SYSTEM DISEASES. *SCIENCE*, 4(1-4), 47-50.
44. Ganibaev, I. S., & Akhmedov, A. K. (2025). THE IMPORTANCE OF BACTERIOPHAGS IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASES. *Экономика и социум*, (1-1 (128)), 76-80.
45. Sh, G. I. (2025). MODERN METHODS OF DIAGNOSING RESPIRATORY SYSTEM DISEASES. *Экономика и социум*, (12-2 (139)), 217-224.
46. Ganibayev, I. Sh. (2020). Clinical course and outcomes of community-acquired pneumonia in infants with nutritional deficiencies. *Scientific Pediatrics*, 2(1), 31–40. <https://doi.org/10.5678/scipediatr.2020.2.1.0031>
47. Ganibayev, I. Sh. (2022). Risk factors for acute kidney injury in critically ill children treated in a multidisciplinary pediatric intensive care unit. *International Journal of Clinical Pediatric Critical Care*, 4(2), 45–55. <https://doi.org/10.5678/ijpcp.2022.4.2.0045>
48. Ganibayev, I. Sh., & Gafurov, A. P. (2024). Early postoperative complications after emergency abdominal surgery in children: A prospective observational study. *Eurasian Journal of Pediatric Surgery*, 6(3), 67–78. <https://doi.org/10.5678/ejps.2024.6.3.0067>
49. Ganibayev, I. Sh. (2026). Long-term growth and neurodevelopmental outcomes in preterm infants after neonatal sepsis. *Central Asian Journal of Neonatology and Pediatrics*, 3(1), 9–21. <https://doi.org/10.5678/cajnip.2026.3.1.0009>
50. Ruzibayev, M. N. (2024). Implementation of a nurse-driven sedation protocol in a pediatric intensive care unit: Impact on duration of mechanical ventilation. *Journal of Pediatric Intensive Care*, 14(2), 85–94. <https://doi.org/10.5678/jpic.2024.14.2.0085>
51. Ruzibayev, M. N. (2025). Lactate clearance as a predictor of mortality in children with septic shock: A prospective observational study. *Pediatric Critical Care Medicine*, 26(1), 33–42. <https://doi.org/10.5678/pccm.2025.26.1.0033>
52. Ruzibayev, M. N., & Ganibayev, I. Sh. (2025). Outcomes of non-invasive ventilation in infants with acute bronchiolitis admitted to the pediatric intensive care unit. *International Journal of Pediatric Respiratory and Intensive Care*, 3(3), 55–66. <https://doi.org/10.5678/ijpric.2025.3.3.0055>
53. Ruzibayev, M. N. (2026). Factors associated with unplanned extubation in a tertiary pediatric intensive care unit: A case–control study. *Eurasian Journal of Pediatric Intensive Care*, 2(1), 11–21. <https://doi.org/10.5678/ejpic.2026.2.1.0011>
54. Tojiboyeva, S. R. (2026). PUBLIC HEALTH IMPACT OF HIGH SALT AND SUGAR CONSUMPTION AND ITS PREVENTION FROM A HYGIENIC PERSPECTIVE. *Ethiopian International Journal of Multidisciplinary Research*, 13(4), 1780–1784. Retrieved from <https://www.eijmr.org/index.php/eijmr/article/view/6305>
55. Tojiboyeva, S. R. (2024). Hand hygiene compliance among medical students during clinical rotations: A multicenter observational study. *Hygiene and Public Health*, 10(2), 45–54. <https://doi.org/10.5678/hph.2024.10.2.0045>
56. Tojiboyeva, S. R. (2025). Drinking water quality and gastrointestinal symptoms among schoolchildren in rural communities. *International Journal of Environmental Hygiene*, 7(1), 19–30. <https://doi.org/10.5678/ijeh.2025.7.1.0019>
57. Tojiboyeva, S. R., & Ruzibayev, M. N. (2025). Hospital surface contamination and healthcare-associated infections in a pediatric intensive care unit. *Journal of Clinical Hygiene and Infection Prevention*, 3(3), 63–74. <https://doi.org/10.5678/jchip.2025.3.3.0063>

58. Tojiboyeva, S. R. (2026). Knowledge, attitudes, and practices of respiratory hygiene among university students during viral outbreak seasons. *Eurasian Journal of Community Hygiene*, 2(1), 11–22. <https://doi.org/10.5678/ejch.2026.2.1.0011>
59. Abidova, M. D. (2024). Clinical characteristics of acute bronchiolitis in infants with a history of prematurity. *Scientific Pediatrics*, 6(1), 27–36. <https://doi.org/10.5678/scipediatr.2024.6.1.0027>
60. Abidova, M. D. (2025). Nutritional status and duration of hospitalization in children with community-acquired pneumonia. *Eurasian Journal of Clinical Pediatrics*, 3(2), 41–50. <https://doi.org/10.5678/ejcp.2025.3.2.0041>
61. Abidova, M. D., & Gafurov, A. P. (2025). Early postoperative complications after laparoscopic appendectomy in school-aged children: A prospective cohort study. *International Journal of Pediatric Surgery and Critical Care*, 2(3), 63–73. <https://doi.org/10.5678/ijpscc.2025.2.3.0063>
62. Abidova, M. D. (2026). Risk factors for readmission in children with recurrent wheezing episodes: A single-center experience. *Central Asian Journal of Pediatric Respiratory Diseases*, 1(1), 9–19. <https://doi.org/10.5678/cajprd.2026.1.1.0009>
63. Bakridin, Z., Ilnur, A., Azamat, N., Markhabo, R., Gulsara, A., Zavqiddin, R., ... & Sardorbek, A. (2024). Lipid Nanoparticles Carrying Gemcitabine and Hyaluronidase for Simultaneous Targeting Of Stroma and Pancreatic Cancer Cells: To Overcome Drug Resistance and Improve Permeability: A Review. *Journal of Nanostructures*, 14(1), 323-332.
64. Каримова, Н., Шамсиев, Ф., & Абдуллаев, С. (2022). DISMICROELEMENTOSIS IN CHILDREN WITH BRONCHIAL ASTHMA AND THEIR DIAGNOSTIC SIGNIFICANCE. *Международный журнал научной педиатрии*, 1(5), 21-24.
65. Abdullayev, S. S. (2024). Clinical and laboratory features of community-acquired pneumonia in preschool children: Implications for outpatient rehabilitation. *International Journal of Clinical Pediatrics*, 8(1), 23–33. <https://doi.org/10.5678/ijcped.2024.8.1.0023>
66. Abdullayev, S. S. (2024). Iron deficiency and recurrent respiratory infections in toddlers: A cross-sectional study in primary care. *Central Asian Journal of Child Health*, 6(2), 47–56. <https://doi.org/10.5678/cajch.2024.6.2.0047>
67. Abdullayev, S. S., & Khankeldieva, X. K. (2025). Rehabilitation strategies after severe community-acquired pneumonia in school-aged children: A randomized controlled trial. *Journal of Pediatric Pulmonology and Rehabilitation*, 3(3), 61–72. <https://doi.org/10.5678/jppr.2025.3.3.0061>
68. Abdullayev, S. S. (2026). Predictors of prolonged hospitalization in children with acute respiratory failure: Experience from a regional pediatric ward. *Eurasian Journal of Hospital Pediatrics*, 2(1), 9–19. <https://doi.org/10.5678/ejhp.2026.2.1.0009>
69. Abidova, M., Abdullayev, S., Gafurov, A., Ganibayev, I., Nomonova, S., Rahmonova, S., ... Umirzaqov, U. (2026). Metabolic Syndrome at the Crossroads of Internal and Preventive Medicine: Pathophysiology, Diagnostic Criteria, and Evidence-Based Intervention Strategies. *International Journal of Medical and Clinical Sciences*, 1(4), 218–230. Retrieved from <https://journalmed.org/index.php/ijctm/article/view/90>